Target Name: GUCD1
NCBI ID: G83606
Review Report on GUCD1 Target / Biomarker Content of Review Report on GUCD1 Target / Biomarker
GUCD1
Other Name(s): Protein LLN4 | GUCD1 variant 4 | CG13760 gene product [Drosophila melanogaster] homolog | Protein GUCD1 | Guanylyl cyclase domain containing 1, transcript variant 4 | GUCD1_HUMAN | Protein GUCD1 (isoform d) | guanylyl cyclase domain-containing protein 1 | guanylyl cyclase domain containing 1 | C22orf13 | Guanylyl cyclase domain-containing protein 1 | LLN4

Understanding GUCD1: Potential Drug Target Or Biomarker

GUCD1, also known as Protein LLN4, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the long non-coding RNA (lncRNA) family, which includes proteins that have been implicated in a wide range of biological processes. One of the most promising aspects of GUCD1 is its potential as a drug target or biomarker.

GUCD1 has been shown to play a role in a variety of cellular processes, including cell adhesion, migration, and the regulation of cell growth. It is also involved in the development and maintenance of tissues, such as the liver and pancreas. This makes it an attractive target for drugs that are designed to intervene in these processes and potentially treat a wide range of diseases.

One of the key challenges in studying GUCD1 is its complex structure. While the protein is relatively small, it is involved in a wide range of interactions with other proteins and RNA molecules. This makes it difficult to study and understand its functions in detail. However , researchers have made significant progress in understanding the basic structure and dynamics of the protein.

One of the most significant findings in the study of GUCD1 was its ability to interact with the protein TAF12. TAF12 is a transcription factor that is involved in the regulation of gene expression, and it has been implicated in a wide range of diseases, including cancer . By binding to GUCD1, TAF12 can regulate the activity of the protein and potentially control its functions.

Another study showed that GUCD1 interacts with the protein HDAC10. HDAC10 is a histone deacetylase, which is involved in the regulation of gene expression and DNA structure. By binding to GUCD1, HDAC10 can also regulate the activity of the protein and potentially control its functions.

In addition to its interactions with TAF12 and HDAC10, GUCD1 has also been shown to interact with a variety of other proteins and RNA molecules. This suggests that it plays an important role in the regulation of cellular processes and is likely to be a valuable target for drugs that are designed to intervene in these processes.

GUCD1 is also of interest as a biomarker for a variety of diseases. Its expression has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that GUCD1 may be a useful biomarker for these diseases and could be used to identify new treatments.

In conclusion, GUCD1 is a protein that has significant potential as a drug target or biomarker. Its complex structure and interactions with other proteins and RNA molecules make it difficult to study and understand its functions in detail. However, research into its role in cellular processes and its potential as a biomarker for a variety of diseases is ongoing. Further studies are likely to shed light on its functions and potential as a drug.

Protein Name: Guanylyl Cyclase Domain Containing 1

The "GUCD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUCD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GUCY1A1 | GUCY1A2 | GUCY1B1 | GUCY1B2 | GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26